Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Neulogy Ventures is a Luxembourg-based venture capital fund founded in 2014, managing €65 million in assets. The firm focuses on early-stage technology companies, particularly those established or operating in Slovakia. With over 30 portfolio companies across 10 countries, Neulogy Ventures addresses challenges in technology, climate change, and healthcare.
Neulogy Ventures invests between €200,000 and €3 million in early-stage technology companies, emphasizing innovative solutions in climate, healthcare, and technology. The firm specifically targets mission-driven entrepreneurs with bold ambitions, primarily focusing on small and medium enterprises (SMEs) in Slovakia.
Notable portfolio companies include Anvesana, which utilizes RNAseq analysis for rare genetic disorders; Diagnose.me, a digital platform for medical diagnosis by international specialists; and Eyerim, an online eyewear retailer in Central and Eastern Europe. Other significant investments include Excalibur, providing cybersecurity as a service, and GA Drilling, which develops technology for ultra-deep geothermal energy.
Submit your pitch through their form at neulogy.vc or email your deck to info@neulogy.vc.
Yes, Neulogy Ventures often leads investment rounds, particularly in early-stage funding for companies in their focus sectors.
Neulogy Ventures is open to follow-on investments, especially for companies that demonstrate significant growth and alignment with their mission-driven focus.
The current fund size of Neulogy Ventures is €65 million, which they utilize to support early-stage technology companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.